Misplaced Pages

Tyloxapol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Pharmaceutical drug Pharmaceutical compound
Tyloxapol
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
CAS Number
PubChem CID
DrugBank
ChemSpider
  • None
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.209.660 Edit this at Wikidata
Chemical and physical data
Formula(C15H21O(C2H4O)m)n
Molar massvariable
  (what is this?)  (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.

Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxapol are Exosurf and Alevaire.

References

  1. Sehgal SS, Ewing CK, Richards T, Taeusch HW (January 1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.
  2. Rubin BK, Ramirez O, King M (April 1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–5. doi:10.1378/chest.101.4.1080. PMID 1555424.
  3. "Tyloxapol definition". Drugs.com.
  4. Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN (October 2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and Molecular Pathology. 73 (2): 135–8. doi:10.1006/exmp.2002.2449. PMID 12231215.
Cough and cold preparations (R05)
Expectorants
Mucolytics
Cough suppressants
Opium alkaloids,
opioids,
and derivatives
Other
Stub icon

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories: